Please assess the completion status of the following clinical trial:

Trial Title: Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed advanced or metastatic non-curable solid tumor (if limited to a single lesion and not a candidate for curative surgery or radiation therapy).~* Completed ≥1 conventional therapy.~* Clinically indicated surgery or procedure to collect available tumor in sufficient quantity (golf ball size, pleural or ascites fluid may also be collected) for vaccine processing.~* Subjects that have completed all acceptable therapies that are the current standard of care for their respective diseases.~* Recovered from all toxicities related to prior therapies.~* Subjects with brain metastases treated at least ≥2 months prior to enrollment, without related clinical symptoms and must have a stable neurological exam on the screening evaluation.~* ≥1 measurable or evaluable lesion.~* Age ≥18 years.~* ECOG performance status (PS) 0-1.~* Normal organ and marrow function:~  * Absolute granulocyte count: ≥1,500/mm3~ * Platelets: ≥100,000/mm3~ * Total bilirubin: ≤2 mg/dL~ * AST(SGOT)/ALT(SGPT): ≤2x institutional upper limit of normal~ * Creatinine: \<1.5 mg/dL~* Ability to understand and the willingness to sign a written informed consent document.~* Negative pregnancy test.~Exclusion Criteria:~* Surgery involving general anesthesia, chemotherapy, radiotherapy, steroid therapy, or immunotherapy within 4 weeks prior to entering the study.~* Patient must not have received any other investigational agents within 30 days prior to study entry.~* Patients with known brain metastases unless treated and stable for ≥2 months.~* Patients with mucinous adenocarcinoma.~* Short term (\<30 days) concurrent systemic steroids ≤ 0.125 mg/kg prednisone per day (maximum 10 mg/day) and bronchodilators (inhaled steroids) are permitted; other steroid regimens and/or immunosuppressives are excluded. Patients requiring steroids following previous CNS radiation for metastatic disease are excluded.~* Prior splenectomy.~* Prior malignancy (excluding nonmelanoma carcinomas of the skin) unless in remission for ≥2 years.~* Kaposi's Sarcoma.~* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~* Patients who are pregnant or nursing.~* Patients who are HIV positive.~* Patients with chronic Hepatitis B and C infection.~* Patients with a history of autoimmune diseases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TAG Vaccine 1 x 10^7 cells/ injection (Type: EXPERIMENTAL): TAG Vaccine 1 x 10\^7 cells/injection
- TAG Vaccine 2.5 X 10^7 cells/injection (Type: EXPERIMENTAL): TAG Vaccine 2.5 X 10\^7 cells/injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues